Q1 2025 Orexo AB Earnings Call Transcript
Key Points
- Orexo AB (LTS:0H19) reported stable revenue in both SEK and US dollars compared to last year, with a slight increase driven by lower inventory decline.
- The company achieved a positive cash flow from operations, indicating effective financial management.
- Successful clinical trials for OX640 have attracted significant partner interest, with several companies conducting due diligence.
- Orexo AB (LTS:0H19) has a natural hedge against currency fluctuations due to a significant portion of expenses being in US dollars.
- The company is optimistic about reaching a partnership agreement for OX640 later this year, which could enhance future growth prospects.
- Orexo AB (LTS:0H19) faced challenges due to changes in Medicare policies in the US, impacting volume and pricing.
- The strengthening of the SEK against the US dollar negatively impacted the company's cash position.
- There are ongoing uncertainties with the FDA, causing delays in drug approvals and impacting timelines for product launches.
- The company experienced a decline in volumes for its main product, Subsol, particularly due to high deductibles and Medicare policy changes.
- Market volatility and geopolitical factors have slowed down potential strategic partnerships and business development activities.
Thank you very much and welcome to all of you dialing into this first quarter presentation. So, the first quarter for, it feels strange, but it feels a little like it's been less eventful, at least compared to our 4th 4th quarter where we both had a legal settlement and also a larger legal restructuring of our balance sheet. I think this year has started very much in line with our expectations.
We did know that there are some Challenges are from commercial, the commercial side and the changes of Medicare system of Medicare policies in the US, we were, of course, unaware of all of the macro volatility that we are seeing, but here it actually feels like we have been insulated, at least so far from a lot of the changes that has been happening on a more geopolitical and macro basis, and I'll come back to that a little later.
Moving into the presentation, first the legal disclaimer and a short presentation of the agenda for today, where I will talk a little about the summary of the quarter, go through some of the business
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
